Sami Ibrahimi
Impact in
- Oncology top 10%
- CAR-T cell therapy research
- Cancer Immunotherapy and Biomarkers
- Pathology and Forensic Medicine top 10%
- Lymphoma Diagnosis and Treatment
Papers in
- Oncology 17
- CAR-T cell therapy research 7
- Cancer Immunotherapy and Biomarkers 5
- Inflammatory Biomarkers in Disease Prognosis 2
-
- Lymphoma Diagnosis and Treatment 13
- Co-authors
- Jeremy S. Abramson (5 shared papers)Alessandro Previtali (4 shared papers)Alessandro Crotta (4 shared papers)Koji Izutsu (5 shared papers)Bertram Glaß (5 shared papers)Mohamad Cherry (4 shared papers)Matthew A. Lunning (5 shared papers)Pim Mutsaers (5 shared papers)
- Journals
- Blood (10 papers)Journal of Clinical Oncology (4 papers)Blood Advances (2 papers)Journal of Personalized Medicine (1 paper)Future Oncology (1 paper)
- Partner nations
- United StatesJapanNetherlands
In The Last Decade
Sami Ibrahimi
29 papers receiving 384 citations
Sami Ibrahimi's Hit Papers
Peers
Comparison fields: 5 of 47
- Oncology 277
- Pathology and Forensic Medicine 158
- Genetics 66
- Internal Medicine 20
- Hematology 47
Countries citing papers authored by Sami Ibrahimi
This map shows the geographic impact of Sami Ibrahimi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sami Ibrahimi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sami Ibrahimi more than expected).
Fields of papers citing papers by Sami Ibrahimi
This network shows the impact of papers produced by Sami Ibrahimi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sami Ibrahimi. The network helps show where Sami Ibrahimi may publish in the future.
Co-authors
The 25 scholars most cited alongside Sami Ibrahimi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 33 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Lisocabtagene maraleucel as second-line therapy for large B-cell lymphoma: primary analysis of the phase 3 TRANSFORM study Hit paper breakdown → | 2022 | 186 |
| 2 | 2017 | 26 | |
| 3 | 2018 | 26 | |
| 4 | 2017 | 23 | |
| 5 | 2017 | 18 | |
| 6 | 2022 | 17 | |
| 7 | 2020 | 13 | |
| 8 | 2024 | 9 | |
| 9 | 2018 | 8 | |
| 10 | 2023 | 6 | |
| 11 | 2024 | 6 | |
| 12 | 2023 | 6 | |
| 13 | 2022 | 6 | |
| 14 | 2021 | 5 | |
| 15 | 2018 | 5 | |
| 16 | 2018 | 4 | |
| 17 | 2020 | 4 | |
| 18 | 2023 | 3 | |
| 19 | 2022 | 3 | |
| 20 | 2023 | 2 |
About Sami Ibrahimi
Sami Ibrahimi is a scholar working on Oncology, Pathology and Forensic Medicine, Genetics, Hematology and Neurology, having authored 33 papers that have together received 387 indexed citations. Recurring topics across this work include Lymphoma Diagnosis and Treatment (13 papers), CAR-T cell therapy research (7 papers), Chronic Lymphocytic Leukemia Research (5 papers), Cancer Immunotherapy and Biomarkers (5 papers), Acute Myeloid Leukemia Research (3 papers), CNS Lymphoma Diagnosis and Treatment (3 papers), Hemophilia Treatment and Research (2 papers) and Inflammatory Biomarkers in Disease Prognosis (2 papers). The work is most often cited by research in Oncology (277 citations), Pathology and Forensic Medicine (158 citations), Genetics (66 citations), Internal Medicine (20 citations) and Hematology (47 citations). Sami Ibrahimi has collaborated with scholars based in United States, Japan and Netherlands. Frequent co-authors include Jeremy S. Abramson, Alessandro Previtali, Alessandro Crotta, Koji Izutsu, Bertram Glaß, Mohamad Cherry, Matthew A. Lunning, Pim Mutsaers, Sandrine Montheard and Scott R. Solomon. Their work appears in journals such as Blood, Journal of Clinical Oncology, Blood Advances, Journal of Personalized Medicine and Future Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.